Cite
HARVARD Citation
Knox, J. et al. (n.d.). P-187A phase 3 study of durvalumab with or without bevacizumab as adjuvant therapy in patients with hepatocellular carcinoma (HCC) who are at high risk of recurrence after curative hepatic resection. Annals of oncology. p. . [Online].